Eli Lilly announces that it has reached a settlement agreement with Totality Medispa, a company with which the laboratory had filed a series of lawsuits in 2023.

Eli Lilly reports that the agreement will require Totality Medispa to make a monetary payment and prohibit it from engaging in 'certain conduct', including ceasing to claim to sell FDA-approved Mounjaro or Zepbound products.

The agreement requires Totality to comply with federal law for its compounded products, report adverse events to the FDA, and clearly state that its tirzepatide compounded products are not FDA-approved.

In addition, Totality will no longer use the Lilly trademark or make misleading statements.

Lilly points out that only its version of tirzepatide is FDA-approved, and that unapproved products pose health risks to patients.


Copyright (c) 2024 CercleFinance.com. All rights reserved.